AlloVir Inc (NASDAQ:ALVR) does about 356.20K shares in volume on a normal day but saw 223406 shares change hands in the recent trading day. The company now has a market cap of 56.77M USD. Its current market price is $0.47, marking an increase of 5.38% compared to the previous close of $0.45. The 52 week high reached by this stock is $1.05 whilst the lowest price level in 52 weeks is $0.40.
AlloVir Inc (ALVR) has a 20-day trading average at $0.4876 and the current price is -54.84% off the 52-week high compared with 17.93% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.6427 and its 200-day simple moving average is $0.7353. If we look at the stock’s price movements over the week, volatility stands at 12.03%, which decreases to 9.12% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 42.06 to suggest the stock is neutral.
The consensus objective for the share price is $0.90, suggesting that the stock has a potential upside of 47.78% over the period.
FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Sell the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 26, 2023 when BofA Securities downgraded the stock to “Underperform” and issued a price target of between $17 and $1.
The current price level is -2.75%, -26.22%, and -35.51% away from its SMA20, SMA50, and SMA200 respectively, with the ALVR price moving above the 50-day SMA on current market day. AlloVir Inc (ALVR) stock is up 3.76% over the week and -13.77% over the past month. Its price is -30.24% year-to-date and -38.05% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and -0.42 for whole year.
To reach the target analysts have set, the stock logically needs to grow 47.78 percent from here.
Outstanding shares total 115.44M with insiders holding 49.12% of the shares and institutional holders owning 41.79% of the company’s common stock. The company has a return on investment of -82.73% and return on equity of -63.33%. The beta has a value of 0.61. Price to book ratio is 0.45.
